ProDesign Denmark has added four shapes in six colours each in the Essential Collection (models 1748-1751). By using transparent colour all the way through the lamination, ProDesign has obtained a more refined look, where the wire core becomes a precious decoration.
University of Alberta Begins First Gene Therapy Trial for Choroideremia in Canada
The University of Alberta has recently begun the enrolling and dosing of subjects in a Phase II clinical trial for a gene therapy treatment of choroideremia, a rare inherited disorder where the capillaries of the choroid degenerate, causing blindness by around middle age.
This gene therapy, in which a viral vector carrying a working copy of the REP1 gene is introduced via sub-retinal injection, was developed by NightstaRx, a UK-based biopharmaceutical company, specializing in the development of therapies for retinal dystrophies. The current phase of this trial involves six subjects, all of them men.
Ian MacDonald, Professor of Ophthalmology and Visual Sciences at the University of Alberta and leader of the clinical research team, says, “It’s a great privilege to be able to do something very positive for people with choroideremia. People have hoped for this for a long time.”
Further Information: http://www.albertahealthservices.ca/11502.asp
ZEISS DriveSafe Launching August 3, 2015
Launching August 3, 2015: A new solution from ZEISS to combat visual challenges when driving.
Most drivers are exposed to difficult driving conditions that impact their vision, such as driving in rain, snow or fog, and of course driving at night. For most, this can be a major source of stress – in fact, over two thirds of adults report difficulty driving in these challenging visual conditions.
Zeiss is very excited to announce the launch of an innovative lens solution from ZEISS: ZEISS DriveSafe – a lens and coating combo to combat these challenges. Call at 1-800-268-6489 or visit www.zeiss.ca/drivesafe to learn more. Or reach out to your local ZEISS representative.
Essilor of America to Acquire Vision Source US
Earlier this morning European time, Vision Source announced that it has entered into an agreement whereby Essilor of America will acquire a majority stake in the Vision Source network. Subject to regulatory approvals, the deal is expected to close over the next couple of months. Specific terms of the acquisition were not disclosed.
VMAIL reports that Vision Source’s Canadian assets, which consisted of 95 franchisees, were transferred to FYidoctors in 2013 and will continue to be managed by that company headed by CEO Alan Ulsifer, OD. Vision Source founder, Glenn Ellisor said, “Vision Source Canada is not part of the transaction. We have a marketing agreement with FYidoctors. I spoke with Al Ulsifer, and he agreed that our relationship will continue.”
In the US, according the Vision Source press release, Vision Source is expected to become a wholly-owned subsidiary of Essilor of America and will continue to be managed independently by the current management team.
Further information available at:
Vision Monday
Vision Source
Aspex Eyewear Extends Greg Norman License Through 2025
Aspex Eyewear Group, based in Mont-Royal, Quebec, and Great White Shark Enterprises, the company founded by golfing legend Greg Norman, announced on July 27 that they have renewed the licensing agreement for Greg Norman Eyewear through 2025.
The Greg Norman Eyewear collection first launched in 2011 and now includes prescription glasses, performance sunglasses and reading glasses. In addition to Greg Norman, Aspex also manufactures EasyClip, EasyTwist and BMW brand eyewear, among others.
Thierry Ifergan, CEO of Aspex Eyewear Group, said about the agreement, “We are so proud of our partnership with Greg Norman. It has been an absolute pleasure working together and contributing to the brand’s tremendous growth throughout the years.”
Further information: https://www.gregnormaneyewear.com/aspex-gwse-extend-through-2025.php

